dasiglucagon · Zegalogue

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Severe Hypoglycemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Also approved (1)
EU
  • Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
Product first approved 2024EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Severe Hypoglycemia
NCT05378672 · Zealand Pharma
2023-05-09 – 2024-12-03 · Hypoglycemia, Type 1 Diabetes
What this study did
NCT03216226 · Zealand Pharma
2017-06-28 – 2018-02-13 · Hypoglycemia, Diabetes Mellitus, Type 1
What this study did
Other / comorbidity
NCT03941236 · Zealand Pharma
2019-05-02 – 2026-05-26 · Congenital Hyperinsulinism
What this study did
NCT03777176 · Zealand Pharma
2019-02-07 – 2020-10-05 · Congenital Hyperinsulinism
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT04172441 · Zealand Pharma
2020-06-19 – 2022-03-07 · Congenital Hyperinsulinism
What this study did
NCT03840278 · Massachusetts General Hospital
2019-05-15 – 2019-07-03 · Type 1 Diabetes Mellitus
What this study did
Phase 2 (9)
Severe Hypoglycemia
NCT04824872 · Zealand Pharma
2023-02 – 2023-02 · Hypoglycemia, Glucose Metabolism Disorders
What this study did
NCT04836273 · Filip Krag Knop
2021-08-20 – 2022-12-15 · Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia
What this study did
NCT04764968 · Steno Diabetes Center Copenhagen
2021-04-27 – 2022-01-28 · Type 1 Diabetes, Hypoglycemia
What this study did
NCT04449692 · Steno Diabetes Center Copenhagen
2020-07-02 – 2021-01-04 · Type 1 Diabetes, Hypoglycemia
What this study did
NCT03984370 · University Hospital, Gentofte, Copenhagen
2019-09-18 – 2020-02-26 · Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia
What this study did
NCT02660008 · Zealand Pharma
2016-01 – 2016-06 · Hypoglycemia
What this study did
Other / comorbidity
NCT05454709 · Inreda Diabetic B.V.
2023-12-29 – 2023-12-29 · Diabetes Mellitus, Type 1
What this study did
NCT02971228 · Zealand Pharma
2016-11 – 2017-06-07 · Diabetes Mellitus, Type 1
What this study did
NCT02916251 · Zealand Pharma
2016-12-01 – 2017-04-05 · Diabetes Mellitus Type 1
What this study did
Phase 1 (4)
Severe Hypoglycemia
NCT04192019 · Insel Gruppe AG, University Hospital Bern
2023-04 – 2024-06 · Type 1 Diabetes, Hypoglycemia
What this study did
NCT03735225 · Zealand Pharma
2018-11-07 – 2019-06-24 · Hypoglycemia
What this study did
NCT02390141 · Zealand Pharma
2015-04 – 2015-08 · Hypoglycemia
What this study did

Competitive landscape

Other Glucagon receptor (agonist) drugs

Nasal Glucagon. Compare all 2 Glucagon receptor (agonist) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Severe Hypoglycemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dasiglucagon (Zegalogue): this drugApprovedPeptideGlucagon receptor (agonist)Partial signal
NCT03378635: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12)
NCT03667053: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 30 minutes (95% CI 20 to 45) | GlucaGen® 1.0 mg 10 minutes (95% CI 8 to 12)
Nasal Glucagon (Baqsimi)ApprovedPeptideGlucagon receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.